Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Core Insights - Ernexa Therapeutics has established a new subsidiary, ErnexaTX2, to support the preclinical development of its lead program, ERNA-101, for ovarian cancer and to prepare for clinical activities anticipated in 2026 [1][3]. Company Developments - The formation of ErnexaTX2 demonstrates the company's commitment to the Texas ecosystem and its readiness for clinical manufacturing, regulatory interactions, and site activation in the future [2]. - Ernexa is advancing its infrastructure in anticipation of Investigational New Drug (IND)-enabling activities, with ERNA-101 on track for IND-enabling studies in 2025 and first-in-human studies targeted for 2026 [3]. Product Information - ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells, while ERNA-102 targets inflammation to treat autoimmune diseases [5]. - The company's core technology involves engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), providing a scalable, off-the-shelf treatment option [4].